Xylo Bio

Xylo Bio

Private
Boulder, ColoradoHealthcare & Life Scienceshttps://xylo.bio

Last Round

Grant

Oct 28, 2024

Total Funding Raised

$14.25M

Momentum Score

50 /100

Company Overview

Xylo Bio is a biotechnology company that develops targeted neuroplastogen therapies designed to rewire neural circuits and restore brain function for patients with psychiatric and neurological disorders.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology, Mental Health, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Application

Keywords

neuroplastogenscomputational drug discoveryAI drug discoverynon-hallucinogenic drugssmall molecule drugspsychedelics 2.0neuroplasticitypsychoplastogensnon-hallucinogenic psychedelicsin silico drug designmental health therapeuticsdrug discovery platformmajor depressive disorderCNS therapeuticssubstance use disorderpre-clinical biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Xylo Bio Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Xylo Bio Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
GrantOct 28, 2024
SeedJun 3, 2024
SeedOct 27, 2022
Pre SeedOct 1, 2021

Key People

Founding team and executive leadership

Sam Banister

Co-founder And Chief Scientific Officer

Founding Team

Xylo Bio Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 16, 2026

    Monthly visitors increased 135% MoM, reaching 8.6K.

  • Oct 1, 2025

    Planning Phase I trials for neurotherapeutics with TGA and FDA.

Xylo Bio Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Xylo Bio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Xylo Bio's valuation, stock price, and market status.

Firmographic Details

HeadquartersBoulder, Colorado
Employee Range31
Year Founded2021
Last FundingOct 28, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.